

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the **SUPPLEMENTARY INFORMATION** section of this Notice to Neurala Bio, Inc. (Neurala), headquartered in Delaware.

DATES: Only written comments and/or applications for a license which are received by the National Center for Advancing Translational Sciences' Office of Strategic Alliances on or before June 2, 2025 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jasmine Kalsi, M.S., Licensing and Patenting Manager, Office of Strategic Alliances, Telephone: 301-435-0129; Email: jasmine.kalsi@nih.gov.

SUPPLEMENTARY INFORMATION:

Intellectual Property

“C-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same”

- (1) U.S. Patent Application No. 16/976,012, HHS Ref. No. E-253-2017-0-US-03, which was issued as Patent Number 11,649,218 on May 16, 2023
- (2) Chile Patent Application No. 2317-2020, HHS Ref. No. E-253-2017-0-CL-04, which was issued as Patent Number CL67.840 on August 2, 2023
- (3) U.S. Patent Application No. 18/128,603, HHS Ref. No. E-253-2017-0-US-02, filed on March 30, 2023 (Pending)

The patent rights in these inventions have been either assigned and/or exclusively licensed to the government of the United States of America and Pontificia Universidad Catolica de Chile.

The prospective exclusive license territory may be worldwide, and the field of use may be limited to the following:

“Use of NCGC00373060, also known as “NEUROTINIB” and its analogs for the treatment of central nervous system disorders, including Epilepsy, Parkinson’s Disease, Lysosomal Storage Disorders (Niemann Pick C and A, Tay-Sachs, Gaucher’s Disease), and Alzheimer’s Disease.”

The inventions relate to a series of novel compounds that inhibit c-Abl tyrosine kinase by binding to an allosteric site of the c-Abl tyrosine kinase. These compounds have favorable tolerability, high potency, high selectivity, good brain penetration, and robust efficacy. All of this allows them to potentially treat diseases such as cancers or neurodegenerative disease.

The compounds of the subject inventions can be used individually or in combination to develop new therapies to treat diseases involving the c-Abl tyrosine kinase, specifically diseases resulting from overexpression of c-Abl tyrosine kinase. The diseases resulting from overexpression of c-Abl tyrosine kinase include frontal temporal dementia associated with ALS, primary lateral sclerosis, Sly syndrome, glioblastoma, neuroblastoma and viral pathogenesis resulting from HV.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Center for Advancing Translational Sciences receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 12, 2025.

Joni L. Rutter,

Director, Office of the Director, National Center for Advancing Translational Sciences.

[FR Doc. 2025-08742 Filed 5-15-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Minority Health and Health Disparities; Cancellation of Meeting

Notice is hereby given of a change in the meeting of the National Institute on Minority Health and Health Disparities Special Emphasis Panel, June 23, 2025, 10:00 a.m. to June 27, 2025, 6:00 p.m., National Institutes of Health, NIMHD, DEM II, Suite 800, 6707 Democracy Boulevard, Bethesda, MD 20892 which was published in the **Federal Register** on April 9, 2025, FR Doc 2025-06092, 90 FR 15255.

This meeting notice is to cancel the meeting scheduled June 18, 2025. This meeting will not be rescheduled.

Dated: May 13, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-08748 Filed 5-15-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Office of Research Infrastructure Programs Special Emphasis Panel; (ZOD1), STOD Member Conflict.

Date: June 17, 2025.

Time: 11:00 a.m. to 04:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (Video Assisted Meeting).

Contact Person: Stephanie Hicks, Scientific Review Officer (SRO), Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480-5710, stephanie.hicks@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: May 13, 2025.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2025-08749 Filed 5-15-25; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection: 30-Day Comment Request; Collection of Customer Service, Demographic, and Smoking/Tobacco Use Information From the National Cancer Institute’s (NCI) Cancer Information Service (CIS)

AGENCY: National Institutes of Health, Health and Human Services.

ACTION: Notice.

SUMMARY: In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide an

opportunity for public comment on proposed data collection projects, the National Institutes of Health, National Cancer Institute (NCI) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

DATES: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

ADDRESSES: Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Candace Maynard, Branch Chief, Cancer Information Service Branch, CISB/OCPL, 9609 Medical Center Drive, Rockville, MD 20850, or call non-toll-free number 240-276-6657 or email your request, including your address to: deatonc@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

SUPPLEMENTARY INFORMATION: This proposed information collection was previously published in the **Federal Register** on October 7, 2024 (89 FR 81088) and allowed 60 days for public comment. One public comment was received. The purpose of this notice is to allow an additional 30 days for public comment. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the

respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

In compliance with section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

Proposed Collection Title: Collection of Customer Service, Demographic, and Smoking/Tobacco use Information from the National Cancer Institute’s (NCI) Cancer Information Service (CIS), 0925-0208, Expiration Date 3/31/2025, REINSTATEMENT WITH CHANGE, National Cancer Institute (NCI), National Institutes of Health (NIH).

Need and Use of Information Collection: The National Cancer Institute (NCI) currently collects: (1) customer service and demographic information from clients of the Cancer Information Service (CIS) to properly plan, implement, and evaluate cancer education efforts; (2) smoking/tobacco use behavior of individuals seeking NCI’s smoking cessation assistance to provide smoking cessation services tailored to the individual client’s needs and track their smoking behavior at follow up. This is a request for OMB to approve a revised submission for an additional three years to provide ongoing customer service and collection of demographic information from CIS clients for the purpose of program planning and evaluation.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 6,343 hours.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Category of respondent	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hours
Demographic & Customer Satisfaction Questions (Appendix 1A or 1AB).	Individuals	15,754	1	3/60	788
Live Help Questions (Appendix 1B)	Individuals	17,589	1	2/60	586
Smoking Cessation “Intake” Questions (Appendix 1C)	Individuals	8,839	1	6/60	884
Smoking Call Backs (Appendix 1D)	Individuals	8,840	1	4/60	589
VA Call Backs (Appendix 1E)	Individuals	26,055	1	4/60	1,737
Cancer Info Call Backs (Appendix 1F)	Individuals	1,841	1	4/60	123
Email Intake Form (Appendix 2)	Individuals	9,740	1	10/60	1,623
Demographic & Customer Satisfaction Questions (Appendix 9)	Individuals	400	1	2/60	13
Totals	89,058	6,343